Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients

Abstract

Troglitazone significantly reduces circulating leptin levels at clinical doses. It may affect the eating behavior of poorly controlled NIDDM patients through the improvement of glycemic control and/or the reduction of circulating leptin.

PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

“…90 This may be explained by lowered blood levels of nutritional substrates such as FFA and glucose, lowered insulin levels, or perhaps lowering of leptin levels as reported by Shimizu et al, 90 or by other hypothalamic changes secondary to an improved glucose homeostasis. In accordance with this, a relatively reduced insulin secretion (ie higher insulin sensitivity) have been associated with subsequent increased body weight gain.…”

Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

“…17,18 This change in fat distribution may explain in part the improvement in glycemic control despite an overall increase in body weight. 19 A decrease in leptin levels and an increase in appetite have been seen with troglitazone treatment 20 ; however, it is not clear if weight gain associated with rosiglitazone or pioglitazone can be attributed to this effect. Fluid retention, of course, is another potential cause of increased body weight.…”

Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes

“…Although HOMA-IR is used as an index of insulin resistance in type 2 diabetic patients (20)(21)(22)(23), its relation with clamp IR during the clinical course of type 2 diabetic patients has not been elucidated as of yet. In the present study, the slope and intercept of the regression lines between HOMA-IR and clamp IR did not significantly differ before and after treatment; this finding suggests that HOMA-IR is a reliable index of insulin resistance for the follow-up of type 2 diabetic patients.…”